Drug for leukaemia can lead to heart failureBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7561.218-d (Published 27 July 2006) Cite this as: BMJ 2006;333:218
Quebec David Spurgeon
A drug for chronic myelogenous leukaemia, imatinib (which is marketed as Glivec in the United Kingdom and Gleevec in the United States), can destroy cardiac cells and lead to severe left ventricular dysfunction and heart failure, says a new report.
“On the basis of our findings, we suggest that a thorough examination of the issue of imatinib-induced left ventricular dysfunction should be undertaken to define the magnitude of the risk,” say the authors of the report, which was published online ahead of print publication on 23 July in Nature Medicine (www.nature.com/naturemedicine, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial